Paper39563449
Semaphorin 5A promotes Th17 differentiation via PI3K-Akt-mTOR in systemic lupus erythematosus.
Chen X and 7 others. Arthritis Res Ther, 2024. Cited by 6 papers, by iCite.
Cite this record
ConductScience Library. Semaphorin 5A promotes Th17 differentiation via PI3K-Akt-mTOR in systemic lupus erythematosus. Papers, record 39563449. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/39563449
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Semaphorin 5A promotes Th17 differentiation via PI3K-Akt-mTOR in systemic lupus erythematosus.
- PubMed
Topics19
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Lupus Erythematosus, Systemic | Major topic |
| Semaphorins | Major topic |
| Th17 Cells | Major topic |
| Cell Differentiation | Major topic |
| Proto-Oncogene Proteins c-akt | Major topic |
| TOR Serine-Threonine Kinases | Major topic |
| Phosphatidylinositol 3-Kinases | Major topic |
| Humans | |
| Female | |
| Adult | |
| Male | |
| Signal Transduction | |
| Nerve Tissue Proteins | |
| Middle Aged | |
| Young Adult | |
| Cells, Cultured | |
| Flow Cytometry | |
| Blotting, Western | |
| Enzyme-Linked Immunosorbent Assay |
Source PubMed
Grants2
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by |
|---|---|---|---|---|
| No.2024ZL099 | The Traditional Chinese Medicine Science and Technology Project of Zhejiang Province | PubMed | ||
| No. 82271817 | National Natural Science Foundation of China | PubMed |
Source PubMed
References40
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 23913957 | Mechanistic target of rapamycin activation triggers IL-4 production and necrotic death of double-negative T cells in patients with systemic lupus erythematosus. | J Immunol | 2013 | https://conductscience.org/library/papers/23913957 | PubMed |
| 2 | 32917979 | IL-17 sustains the plasma cell response via p38-mediated Bcl-xL RNA stability in lupus pathogenesis. | Cell Mol Immunol | 2021 | https://conductscience.org/library/papers/32917979 | PubMed |
| 3 | 15218527 | Plexin-B3 is a functional receptor for semaphorin 5A. | EMBO Rep | 2004 | https://conductscience.org/library/papers/15218527 | PubMed |
| 4 | 29213125 | The role of semaphorins in immune responses and autoimmune rheumatic diseases. | Nat Rev Rheumatol | 2018 | https://conductscience.org/library/papers/29213125 | PubMed |
| 5 | 35059729 | Extracellular domain of semaphorin 5A serves a tumor‑suppressing role by activating interferon signaling pathways in lung adenocarcinoma cells. | Int J Oncol | 2022 | https://conductscience.org/library/papers/35059729 | PubMed |
| 6 | 27306639 | Systemic lupus erythematosus. | Nat Rev Dis Primers | 2016 | https://conductscience.org/library/papers/27306639 | PubMed |
| 7 | 33581650 | Rapamycin alleviates renal damage in mice with systemic lupus erythematosus through improving immune response and function. | Biomed Pharmacother | 2021 | https://conductscience.org/library/papers/33581650 | PubMed |
| 8 | 9324032 | Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. | Arthritis Rheum | 1997 | https://conductscience.org/library/papers/9324032 | PubMed |
| 9 | 36087549 | Rapamycin-encapsulated costimulatory ICOS/CD40L-bispecific nanoparticles restrict pathogenic helper T-B-cell interactions while in situ suppressing mTOR for lupus treatment. | Biomaterials | 2022 | https://conductscience.org/library/papers/36087549 | PubMed |
| 10 | 34540858 | The Th17/IL-17 Axis and Kidney Diseases, With Focus on Lupus Nephritis. | Front Med (Lausanne) | 2021 | https://conductscience.org/library/papers/34540858 | PubMed |
| 11 | 30654587 | Role of Semaphorins in Immunopathologies and Rheumatic Diseases. | Int J Mol Sci | 2019 | https://conductscience.org/library/papers/30654587 | PubMed |
| 12 | 3114409 | In vivo treatment of (NZB X NZW)F1 lupus-like nephritis with monoclonal antibody to gamma interferon. | J Exp Med | 1987 | https://conductscience.org/library/papers/3114409 | PubMed |
| 13 | 32528480 | T Cell Metabolism: A New Perspective on Th17/Treg Cell Imbalance in Systemic Lupus Erythematosus. | Front Immunol | 2020 | https://conductscience.org/library/papers/32528480 | PubMed |
| 14 | 33200217 | Sirolimus for patients with connective tissue disease-related refractory thrombocytopenia: a single-arm, open-label clinical trial. | Rheumatology (Oxford) | 2021 | https://conductscience.org/library/papers/33200217 | PubMed |
| 15 | 21835343 | Class 5 transmembrane semaphorins control selective Mammalian retinal lamination and function. | Neuron | 2011 | https://conductscience.org/library/papers/21835343 | PubMed |
| 16 | 30972208 | miR-125a-3p decreases levels of interlukin-17 and suppresses renal fibrosis via down-regulating TGF-β1 in systemic lupus erythematosus mediated Lupus nephritic mice. | Am J Transl Res | 2019 | https://conductscience.org/library/papers/30972208 | PubMed |
| 17 | 24683191 | Mechanistic target of rapamycin complex 1 expands Th17 and IL-4+ CD4-CD8- double-negative T cells and contracts regulatory T cells in systemic lupus erythematosus. | J Immunol | 2014 | https://conductscience.org/library/papers/24683191 | PubMed |
| 18 | 17538187 | Chemokine receptor CXCR3 mediates T cell recruitment and tissue injury in nephrotoxic nephritis in mice. | J Am Soc Nephrol | 2007 | https://conductscience.org/library/papers/17538187 | PubMed |
| 19 | 35872102 | Abnormalities of T cells in systemic lupus erythematosus: new insights in pathogenesis and therapeutic strategies. | J Autoimmun | 2022 | https://conductscience.org/library/papers/35872102 | PubMed |
| 20 | 31791181 | Interleukin-17 and lupus: enough to be a target? For which patients? | Lupus | 2020 | https://conductscience.org/library/papers/31791181 | PubMed |
Cited by4
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 6 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42075897 | PPAR-α Agonist Suppresses Expression of Immune Mediators in B Cells in a Murine Model of Systemic Lupus Erythematosus. | Pharmaceuticals (Basel) | 2026 | https://conductscience.org/library/papers/42075897 | PubMed |
| 41893339 | Serum Semaphorin Alterations in Psoriasis: Links to Metabolic Status Rather than Disease Severity. | Metabolites | 2026 | https://conductscience.org/library/papers/41893339 | PubMed |
| 41164222 | The Function of the TGFβ Signaling Pathway in Connective Tissue Diseases: From Biology to Clinical Application. | J Inflamm Res | 2025 | https://conductscience.org/library/papers/41164222 | PubMed |
| 41113857 | Expression levels of interleukin-17 and interferon-γ in peripheral blood and relationship with thyroid function in patients with Hashimoto's thyroiditis. | Front Mol Biosci | 2025 | https://conductscience.org/library/papers/41113857 | PubMed |
Genes12
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Trials
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/39563449
GET https://conductscience.org/api/papers/v1/39563449/references?page=2